Publicaciones en colaboración con investigadores/as de Champalimaud Foundation (33)

2024

  1. A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey

    European Journal of Surgical Oncology, Vol. 50, Núm. 10

  2. EUSOMA quality indicators for non-metastatic breast cancer: An update

    European Journal of Cancer, Vol. 198

  3. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 9, pp. 2706-2732

  4. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines

    European Journal of Nuclear Medicine and Molecular Imaging

  5. Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature

    Journal of Clinical Oncology, Vol. 42, Núm. 10, pp. 1124-1134

  6. Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines

    Breast, Vol. 78

  7. Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network

    European Journal of Cancer, Vol. 196

2023

  1. European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission

    The Lancet Oncology, Vol. 24, Núm. 1, pp. e11-e56

  2. European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care

    European Journal of Cancer, Vol. 187, pp. 105-113

  3. Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP

    Revista Espanola de Patologia, Vol. 56, Núm. 4, pp. 261-270

2022

  1. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

    Breast, Vol. 63, pp. 123-139

  2. The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres

    European Journal of Cancer, Vol. 177, pp. 72-79

2021

  1. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 476-488

  2. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox

    The Lancet Oncology, Vol. 22, Núm. 1, pp. e18-e28

  3. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798

  4. Erratum to “Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: Annals of Oncology 30; 2019: 1194–1220 (Annals of Oncology (2019) 30(8) (1194–1220), (S0923753419312876))

    Annals of Oncology

  5. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

    npj Breast Cancer, Vol. 7, Núm. 1

  6. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

    BMC Cancer, Vol. 21, Núm. 1

  7. Surgical management of the axilla in clinically node‐positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: Current status, knowledge gaps, and rationale for the eubreast‐03 axsana study

    Cancers, Vol. 13, Núm. 7

2020

  1. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 395, Núm. 10218, pp. 132-141